Therma Bright's Venowave VW5 Secures Medicare Reimbursement Status Through HCPCS Code

Therma Bright Inc. has achieved a significant milestone in the compression therapy market with its Venowave VW5 device receiving a permanent Healthcare Common Procedure Coding System code from the U.S. Centers for Medicare and Medicaid Services. This designation makes the Venowave VW5 the only Medicare-approved, reimbursable mobile mechanical compression system available in the United States, providing patients with a lightweight and compact solution for managing post-operative recovery, pain, and swelling issues. The FDA-designated Durable Medical Equipment device offers a simple and comfortable treatment option that now qualifies for Medicare reimbursement, expanding accessibility for patients requiring compression therapy.

The company's market position has been strengthened through strategic distribution partnerships with major medical device distributors. DME Authority, a national distributor, has committed to a substantial inventory purchase including an initial order of 1,750 Venowave VW5 units, representing potential HCPCS code reimbursements of approximately $1.43 million. Another national distributor, Valor Medical, has placed an initial order for 100 units with potential for regular future purchases. These distribution agreements demonstrate growing market acceptance and provide significant revenue potential for Therma Bright in the competitive medical device sector.

The global compression therapy market presents substantial growth opportunities for companies like Therma Bright. According to Straits Research, the market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, with a compound annual growth rate of 7.30%. This growth trajectory indicates increasing demand for compression therapy solutions, positioning Therma Bright to capture market share with its Medicare-reimbursable Venowave VW5 system. The company's strategic focus on compression therapy aligns with market trends toward portable and reimbursable medical devices.

Beyond the Venowave VW5, Therma Bright is developing additional innovative medical technologies that could further strengthen its position in the healthcare market. The company is pursuing FDA classification for its acoustic AI Digital Cough Technology, a remote therapeutic monitoring solution designed to help healthcare providers and epidemiologists collect and analyze respiratory data. This expansion into digital health monitoring represents the company's commitment to innovation beyond compression therapy, potentially creating additional revenue streams and market opportunities in the evolving healthcare technology landscape.